Biotech Values

[Biowatch]

The Motley Fool take on SMMT:

https://www.fool.com/investing/2022/08/22/why-summit-therapeutics-stock-popped-today/

This insider buy couldn't have come at a better time. Summit's share price has been under heavy pressure this year for two key reasons. First, the ongoing bear market has taken a man-with-a-hammer stance toward all cash flow-negative biotech companies in 2022. Summit, for its part, has been no exception to this industry-wide trend.

Second, the U.S. Food and Drug Administration (FDA) informed the company back in July that another phase 3 trial would be required for its Clostridioides difficile infection drug candidate, ridinilazole. Investors were none too pleased with this development, as late-stage trials are both costly and time-consuming.

In short, Summit's shareholder base clearly needed a vote of confidence following these unfortunate events. Duggan's latest stock purchase seems to have delivered on that front…

Is Summit's stock still worth buying? It all depends on your investing horizon and comfort with risk…

…the company is probably a few years away from possibly gaining market access for its lead product candidate.

[Drum roll please: the Motley Fool’s perpetual pitch that you should send them money to get their opinions:]
10 stocks we like better than Summit Therapeutics